Weight loss differences seen between glucagon-like peptide–1 receptor agonists and sodium–glucose cotransporter–2 inhibitors for treatment of type 2 diabetes

医学 减肥 内科学 四分位间距 内分泌学 2型糖尿病 糖尿病 兴奋剂 胰高血糖素样肽1受体 胃肠病学 药理学 二甲双胍 肥胖 受体
作者
Katherine Frieling,Scott V. Monte,David M. Jacobs,Nicole Paolini Albanese
出处
期刊:Journal of the American Pharmacists Association [Elsevier BV]
卷期号:61 (6): 772-777 被引量:5
标识
DOI:10.1016/j.japh.2021.06.015
摘要

Weight loss is an advantageous quality for diabetic medications because it can improve insulin sensitivity and glucose control and reduce cardiovascular risk factors and comorbidities. Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are both preferred agents for use after metformin therapy, and both cause modest weight loss.The aim of this study was to evaluate the difference in weight loss between GLP-1 receptor agonists and SGLT-2 inhibitors in patients with type 2 diabetes (T2D).This was a retrospective study that was conducted at a level 3 patient-centered medical home in Buffalo, NY. The participants were adults with T2D treated with either a GLP-1 receptor agonist or an SGLT-2 inhibitor, in addition to background diabetes medications, between January 1, 2012, and September 20, 2017. The outcome measures included the median weight loss after 6 months of consecutive therapy compared between the 2 antidiabetic classes and the median differences in blood pressure, glycosylated hemoglobin (A1C) levels, and renal function markers compared between the 2 classes.A total of 73 patients were included in the final analysis, with 31 receiving SGLT-2 inhibitors and 42 receiving therapy with GLP-1 receptor agonists. The SGLT-2 inhibitor cohort presented a median weight loss of -2.80 kg (interquartile range [IQR] -5.40 to -1.50), and the GLP-1 receptor agonist cohort presented a median weight loss of -1.15 kg (IQR -3.38 to 0.975) (P = 0.014). There were no statistically significant differences in A1C levels, blood pressure, or renal function markers.SGLT-2 inhibitors, when used in combination with background diabetes regimens, can lead to more statistically significant weight loss than GLP-1 receptor agonists without compromising renal function.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange的应助被Len采纳,获得30
刚刚
mxd1991完成签到,获得积分10
1秒前
yukirao完成签到,获得积分10
1秒前
loudei发布了新的文献求助10
1秒前
研友_5Z4ZA5完成签到,获得积分10
1秒前
脑洞疼的应助被风吹麦浪采纳,获得10
1秒前
无花果的应助被KK采纳,获得10
1秒前
1秒前
2秒前
无极微光的应助被yulu采纳,获得20
2秒前
SM俊完成签到,获得积分10
2秒前
2秒前
molihuakai的应助被董家旭采纳,获得10
2秒前
huww发布了新的文献求助10
3秒前
3秒前
哈哈哈完成签到 ,获得积分10
3秒前
luchong发布了新的文献求助10
3秒前
英吉利25发布了新的文献求助10
3秒前
坦诚发布了新的文献求助10
3秒前
4秒前
雾雪零尘完成签到,获得积分10
5秒前
透射电镜完成签到,获得积分10
5秒前
呼呼哈哈发布了新的文献求助50
5秒前
田様的应助被曾经焦焦采纳,获得10
6秒前
麦当当发布了新的文献求助10
6秒前
噜噜啦完成签到 ,获得积分10
6秒前
彭于彦祖的应助被zzZ5采纳,获得30
6秒前
6秒前
7秒前
qearl发布了新的文献求助10
7秒前
嘿嘿发布了新的文献求助10
7秒前
7秒前
7秒前
JJ完成签到,获得积分10
7秒前
8秒前
小黄发布了新的文献求助10
8秒前
呵呵完成签到,获得积分10
8秒前
8秒前
今天关注了科研通微信公众号
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253